A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novel innovative drug for the treatment of type 2 diabetes

Project Information

AMPK-DIAB

Grant agreement ID: 754268

DOI 10.3030/754268

Project closed

EC signature date 8 February 2017

Start date 1 November 2016

End date 30 June 2018

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Total cost € 2 604 625,00

EU contribution € 1 823 237,50

Coordinated by

BETAGENON AB
Sweden